In memory of an ethical giant, Dr. Ron Heslegrave
Tuesday, June 30, 2020:  Dr. Ron Heslegrave, who chaired the research ethics boards at LTRI / Sinai Health for 20 years, died on June 30th, 2020. 
Lunenfeld-Tanenbaum Research Institute receives new matching gift to fuel COVID-19 research
Thursday, June 25, 2020:  Philanthropists Larry and Judy Tanenbaum have made a new donation of $1 million to fuel COVID-19 research at Sinai Health’s Lunenfeld-Tanenbaum Research Institute (LTRI). Their gift will be used to match all new donations to the LTRI for COVID-19 and other related groundbreaking research. The LTRI ranks in the top one per cent of global academic institutions in molecular and cell biology. A number of its researchers are on the front lines of discovering how best to identify and treat COVID-19, including looking at how the virus spreads and exploring new drug therapies. 
Scientists Discover link between autism and cognitive impairment
Wednesday, January 29, 2020:  A tiny gene fragment may play a pivotal role in why some people with autism also develop mental disabilities, according to new research from scientists at SinaiHealth and the University of Toronto. ‍ Their study, published in the journal MolecularCell, identifies a short gene segment, or microexon, that is crucial for brain development andinformation processing. ‍ Sabine Cordes, a senior investigator at Sinai Health’sLunenfeld-Tanenbaum Research Institute, and Benjamin Blencowe, a professor of molecular genetics in theDonnelly Centre for Cellular and Biomolecular Research, led the study that describes how an absence ofthis segment leads to altered social behaviour in mice, as well as learning and memorydeficits. 
Researchers discover new tool for investigating brain disorders, including dementia and depression
Wednesday, January 22, 2020:  A team of scientists from Canada, the UK and US hasdiscovered a new compound that could lead to better treatments for a host of serious brain disorders,including Alzheimer’s, Parkinson’s disease and depression. ‍ GrahamCollingridge, senior investigator at Sinai Health’s Lunenfeld-Tanenbaum Research Institute anddirector of the Tanz Centre for Neurodegenerative Diseases at the University of Toronto, was part of aninternational consortium of researchers that created a new chemical tool for revealing how specific cellreceptors function in the brain. 
New study sheds light on why non-smokers develop lung cancer
Monday, January 13, 2020:  A problem with the immune system may be why otherwisehealthy, non-smokers develop lung cancer, new research out of Sinai Health shows. ‍ Rayjean Hung, senior investigator at Sinai Health’s Lunenfeld-Tanenbaum Research Institute (LTRI), lookedat whether those with impaired lung function, such as emphysema or COPD, were at an increased risk ofdeveloping lung cancer. 
Sinai Health System Researcher Awarded 2019 EASD-Novo Nordisk Foundation Diabetes Prize for Excellence
Monday, September 9, 2019:  Daniel J. Drucker, a senior investigator at Sinai Health System’s Lunenfeld-Tanenbaum Research Institute and a professor of medicine at University of Toronto, was today announced as the 2019 recipient of the EASD-Novo Nordisk Foundation Diabetes Prize for Excellence.